Navigation Links
Varian's RapidArc Radiotherapy Technology Enables Pioneering Cancer Treatments at Top Dutch Oncology Center
Date:6/18/2009

AMSTERDAM, June 18 /PRNewswire-FirstCall/ -- Doctors in the Netherlands have developed new ways to perform radiosurgery on benign acoustic tumors using fast and precise RapidArc(TM) radiotherapy technology from Varian Medical Systems (NYSE: VAR). This is among the findings in several papers published by the team at VU University Medical Center in Amsterdam.

Radiation oncologist Dr. Frank Lagerwaard and his team compared RapidArc with five-arc dynamic conformal arc radiosurgery for vestibular schwannoma, a benign tumor that affects hearing and balance. "Treatment delivery time after patient setup was less than five minutes versus 20 minutes for dynamic conformal arc radiosurgery," says Dr. Lagerwaard. "We found that RapidArc planning was completed within 30 minutes in all cases."

His team found that the RapidArc plans consistently achieved greater conformity and a reduction in areas of low-dose irradiation compared to conventional radiosurgery. "This, together with the benefits of shorter treatment times, allows us to replace our conventional five-arc radiosurgery technique for vestibular schwannomas with RapidArc," added Dr. Lagerwaard.

RapidArc delivers a precise and efficient treatment in single or multiple arcs of the treatment machine around the patient and makes it possible to deliver image-guided intensity-modulated radiotherapy (IMRT) two to eight times faster than is possible with conventional IMRT. Faster treatments allow for greater precision, since there is less chance of patient or tumor movement during treatment delivery and, with less time on the treatment couch, also allow for greater patient comfort.

Cancer patients at VU University Medical Center are treated on two Varian Clinac(R) 2300 CD linear accelerators, a Trilogy(R) linear accelerator, and the Novalis Tx(TM) radiosurgical suite of products, all equipped with RapidArc capability. The clinical team has published scientific papers on early RapidArc treatments, including research comparing RapidArc volumetric modulated arc therapy with conventional IMRT, in peer review journals.

Dr. Ben Slotman, chairman of the hospital's department of radiation oncology, says, "In the past we treated about fifteen percent of patients with IMRT but now use RapidArc for a much larger number of IMRT indications. In addition to standard head and neck and prostate treatments, a range of new indications, such as whole brain radiotherapy with simultaneous boost to multiple brain metastases, pelvic tumors and small lung tumors are now being treated with RapidArc.

"Our experience so far is that RapidArc planning and delivery is considerably faster than alternative methods," added Dr. Slotman. "We are expanding the range of cancers for which we use RapidArc and we believe we can replace our full stereotactic radiotherapy program with RapidArc, just as has happened with IMRT."

Previous findings by Dr. Wilko Verbakel, medical physicist, describing how RapidArc plans could deliver better dose distributions than is achievable with conventional IMRT for head and neck tumors in less than three minutes, has now been substantiated by actual clinical data on more than 100 such patients who have received RapidArc for this indication.

Similarly, a publication in production on small primary lung tumors by Dr. Verbakel describes how clinical delivery of RapidArc for stereotactic radiotherapy could be completed in as little as ten minutes.

In the year since RapidArc was installed at VU University Medical Center, more than 300 cancer patients have been treated using this fast and precise treatment technology.

"VU University Medical Center was one of the first hospitals in the world to introduce RapidArc a year ago and to my knowledge no other hospital has treated as many patients with this technique," says Rolf Staehelin, Varian's European marketing director. "Our sincere congratulations to everyone in the team at VU for making this happen so quickly. They are carrying out some pioneering work that is making radiotherapy treatments faster and more precise."

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, China, and Europe and in its 79 sales and support offices around the world. For more information, visit http://www.varian.com/


'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital
2. Cancer Patients in North Wales to Gain Access to Varians RapidArc Radiotherapy Treatments
3. Ajou University Hospital Becomes First in Korea to Treat Using RapidArc(TM) Radiotherapy Technology from Varian Medical Systems
4. RapidArc Radiotherapy Technology Enabling Fast, Accurate Treatments for Pennsylvania Cancer Patients
5. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
6. New Mexico Doctors Now Treating Brain and Prostate Cancer With RapidArc Radiotherapy Technology
7. Public Cancer Center Becomes First in South-East Asia to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
8. Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
9. A Fast, New Cancer Fighting Tool Is Now Available in the Houston Area: RapidArc(TM) Radiotherapy Technology from Varian Medical Systems
10. Impac Software Announces Clinical Release of RapidArc Support
11. First RapidArc Radiotherapy Treatment in Italy Takes Place at Leading Milan Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In search of the K. ... theme event of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites ... is sponsored and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), ...
(Date:5/27/2016)... Columbia, SC (PRWEB) , ... May 27, 2016 , ... ... launched a line of classic American timber frame barn kits, which can be found ... are inspired by historic American barn plans, and they highlight the craftsmanship of ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... Texas (PRWEB) , ... May 27, 2016 , ... ... satisfying Army body fat composition regulations. This is the first time that Coolsculpting ... normally screened at least every six months to ensure they meet the prescribed body-fat ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
(Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:5/24/2016)...   , Study met ... bowel cleansing and superiority in , ... of the ascending colon   ... Norgine B.V. today announced new positive data from the phase ... preparation) versus standard 2 litre PEG with ascorbate. The study met ...
Breaking Medicine Technology: